Strong Financial Performance
Balchem reported a strong quarter with consolidated revenues of $240 million, an increase of 4.3% compared to the prior year. Gross margin dollars grew 11.5%, and the gross margin percentage expanded by 230 basis points to 35.6%.
Record Earnings
Earnings from operations reached $48 million, a 10% increase versus the prior year, with record adjusted EBITDA of $64 million, up 7.6%.
Human Nutrition & Health Segment Growth
The Human Nutrition & Health segment generated sales of $152 million, an increase of 5.4% from the prior year, driven by higher sales within the minerals and nutrients business and the food and beverage markets.
Innovative Product Launches
New products include AminoShure-XL in Animal Nutrition & Health and K2VITAL DELTA Fermented and VitaCholine Pro-Flo in Human Nutrition & Health, highlighting ongoing innovation.
Debt Reduction
Balchem reduced its debt by $40 million in the third quarter, ending with net debt of $153 million and a leverage ratio of 0.6.